Unknown

Dataset Information

0

Inhibition of plasma kallikrein by a highly specific active site blocking antibody.


ABSTRACT: Plasma kallikrein (pKal) proteolytically cleaves high molecular weight kininogen to generate the potent vasodilator and the pro-inflammatory peptide, bradykinin. pKal activity is tightly regulated in healthy individuals by the serpin C1-inhibitor, but individuals with hereditary angioedema (HAE) are deficient in C1-inhibitor and consequently exhibit excessive bradykinin generation that in turn causes debilitating and potentially fatal swelling attacks. To develop a potential therapeutic agent for HAE and other pKal-mediated disorders, we used phage display to discover a fully human IgG1 monoclonal antibody (DX-2930) against pKal. In vitro experiments demonstrated that DX-2930 potently inhibits active pKal (Ki = 0.120 ± 0.005 nM) but does not target either the zymogen (prekallikrein) or any other serine protease tested. These findings are supported by a 2.1-Å resolution crystal structure of pKal complexed to a DX-2930 Fab construct, which establishes that the pKal active site is fully occluded by the antibody. DX-2930 injected subcutaneously into cynomolgus monkeys exhibited a long half-life (t½ ? 12.5 days) and blocked high molecular weight kininogen proteolysis in activated plasma in a dose- and time-dependent manner. Furthermore, subcutaneous DX-2930 reduced carrageenan-induced paw edema in rats. A potent and long acting inhibitor of pKal activity could be an effective treatment option for pKal-mediated diseases, such as HAE.

SUBMITTER: Kenniston JA 

PROVIDER: S-EPMC4156074 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications


Plasma kallikrein (pKal) proteolytically cleaves high molecular weight kininogen to generate the potent vasodilator and the pro-inflammatory peptide, bradykinin. pKal activity is tightly regulated in healthy individuals by the serpin C1-inhibitor, but individuals with hereditary angioedema (HAE) are deficient in C1-inhibitor and consequently exhibit excessive bradykinin generation that in turn causes debilitating and potentially fatal swelling attacks. To develop a potential therapeutic agent fo  ...[more]

Similar Datasets

| S-EPMC5355960 | biostudies-literature
| S-EPMC7939394 | biostudies-literature
| S-EPMC6163658 | biostudies-literature
| S-EPMC3057299 | biostudies-literature
| S-EPMC7293249 | biostudies-literature
| S-EPMC4787600 | biostudies-literature
| S-EPMC4815333 | biostudies-literature
| S-EPMC5910183 | biostudies-literature
| S-EPMC7906296 | biostudies-literature
| S-EPMC2699359 | biostudies-literature